Patents by Inventor Laitian XING

Laitian XING has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Application of derivative of clostridium ghonii
    Patent number: 10314809
    Abstract: Application of Derivatives of Clostridium ghonii, especially in the application of Derivatives of Clostridium ghonii MW-DCG-HNCv-18 in preparation of medicines for treating non-small cell lung carcinoma. It also discloses a medicine combining the Derivatives of Clostridium ghonii MW-DCG-HNCv-18 strain with Docetaxel as the active ingredients. According to the invention, the MW-DCG-HNCv-18 strain is found to have specific inhibition effect on non-small cell lung carcinoma for the first time, the inhibition effect on the non-small cell lung carcinoma is significantly superior to that of other known similar strains, and through screening, the MW-DCG-HNCv-18 strain is found to have more prominent inhibition effect on non-small cell lung carcinoma when combined with Docetaxel injection.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: June 11, 2019
    Assignee: SHANDONG XINCHUANG BIOTECHNOLOGY CO., LTD.
    Inventors: Laitian Xing, Yong Wang, Mingqian Wei, Yanqiu Xing, Lianlian Li, Lichao Xing, Guangxia Deng, Hong Meng, Tao Huang, Dongxia Yang
  • APPLICATION OF DERIVATIVE OF CLOSTRIDIUM GHONII
    Publication number: 20170354633
    Abstract: Application of Derivatives of Clostridium ghonii, especially in the application of Derivatives of Clostridium ghonii MW-DCG-HNCv-18 in preparation of medicines for treating non-small cell lung carcinoma. It also discloses a medicine combining the Derivatives of Clostridium ghonii MW-DCG-HNCv-18 strain with Docetaxel as the active ingredients. According to the invention, the MW-DCG-HNCv-18 strain is found to have specific inhibition effect on non-small cell lung carcinoma for the first time, the inhibition effect on the non-small cell lung carcinoma is significantly superior to that of other known similar strains, and through screening, the MW-DCG-HNCv-18 strain is found to have more prominent inhibition effect on non-small cell lung carcinoma when combined with Docetaxel injection.
    Type: Application
    Filed: July 8, 2015
    Publication date: December 14, 2017
    Inventors: Laitian XING, Yong WANG, Mingqian WEI, Yanqiu XING, Lianlian LI, Lichao XING, Guangxia DENG, Hong MENG, Tao HUANG, Dongxia YANG